Skip to main content
. 2016 Feb 8;7(11):12704–12717. doi: 10.18632/oncotarget.7260

Table 3. Clinicopathological and molecular features of 152 serrated lesions and 55 non-serrated adenomas.

Clinicopathological or molecular feature Total N Histological type p
Hyperplastic polyp (HP) Sessile serrated adenoma/polyp (SSA/P) Traditional serrated adenoma (TSA) Non-serrated adenoma
All cases 207 50 51 51 55
Gender
 Male 124 (60%) 36 (72%) 23 (45%) 26 (51%) 39 (71%) 0.0065
 Female 83 (40%) 14 (28%) 28 (55%) 25 (49%) 16 (29%)
Age (mean ± SD) 61.7 ± 10.8 58.9 ± 11.6 57.4 ± 10.8 65.1 ± 11.5 65.3 ± 8.7 < 0.0001
Tumor size (mm) (mean ± SD) 11.0 ± 5.3 9.0 ± 3.7 13.5 ± 6.7 9.9 ± 4.7 11.4 ± 5.4 0.0002
Tumor location
 Rectum and Distal colon 98 (47%) 24 (48%) 5 (9.8%) 38 (75%) 31 (56%) < 0.0001
 Proximal colon 109 (53%) 26 (52%) 46 (90%) 13 (25%) 24 (44%)
BRAF mutation
 Wild-type 107 (52%) 27 (54%) 7 (14%) 19 (37%) 54 (98%) < 0.0001
 Mutant 100 (48%) 23 (46%) 44 (86%) 32 (63%) 1 (1.8%)
CIMP status
 CIMP-low/zero 174 (84%) 46 (92%) 32 (63%) 41 (80%) 55 (100%) < 0.0001
 CIMP-high 33 (16%) 4 (8.0%) 19 (37%) 10 (20%) 0 (0%)
MicroRNA-31
 Low expression (Q1-3) 155 (75%) 39 (78%) 40 (78%) 27 (53%) 49 (89%) < 0.0001
 High expression (Q4) 52 (25%) 11 (22%) 11 (22%) 24 (47%) 6 (11%)
EZH2 expression
 Score 0 (negative) 90 (43%) 18 (36%) 39 (76%) 13 (25%) 20 (36%) < 0.0001
 Score 1 (weak) 83 (40%) 20 (40%) 12 (24%) 23 (45%) 28 (51%)
 Score 2 (moderate) 34 (16%) 12 (24%) 0 (0%) 15 (29%) 7 (13%)
 Score 3 (strong) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)

P-values were calculated by analysis of variance for age and tumor size, and by a chi-square test for all other variables. CIMP, CpG island methylator phenotype; HP, hyperplastic polyp; SSA/P, sessile serrated adenoma/polyp; SD, standard deviation; TSA, traditional serrated adenoma.